


Supplementary Figure 1. Average observed (top) and predicted (bottom) logFIB4 with 95% confidence bands (shaded) over 41 90-day intervals by treatment groups based on the 1:1 matched cohort. *Significant difference between treatment failure and untreated patients at a specific time interval ($P < .05$). The number of patients at each time point is noted at the bottom.

Treated w SVR
 Untreated
 Treatment Failure

	index date	1	2	3	4	5	6	7	8	9	10
Treated w SVR	1632	406	331	274	226	213	187	160	142	107	99
Untreated	1632	281	292	261	224	213	182	143	120	106	84
Treatment Failure		94	131	123	106	92	83	66	58	37	26



Supplementary Figure 2. Average observed (top) and predicted (bottom) logFIB4 with 95% confidence bands (shaded) over 41 90-day intervals by treatment group. The propensity score was estimated without several key covariates. *Significant difference between treatment failure and untreated patients at a specific time interval ($P < .05$). The number of patients at each time point is noted at the bottom.

Treated w SVR
 Untreated
 Treatment Failure

	1	2	3	4	5	6	7	8	9	10
Treated w SVR	95	135	127	112	96	88	73	65	42	31
Untreated	3074	788	688	569	461	441	371	312	254	204
Treatment Failure	1657	281	294	264	225	216	186	143	120	106

Supplementary Table 1. Possible Contraindications to Antiviral Therapy

Evidence of hemoglobinopathy	
Major uncontrolled depressive illness	
Severe psychiatric disease	Schizophrenia Other psychotic disorders Bipolar disorder Select anxiety disorders
Organ transplant (kidney, heart, or lung)	
Select autoimmune conditions	Autoimmune hepatitis Immune thrombocytopenia Myasthenia gravis Multiple sclerosis Systemic lupus erythematosus
Untreated hyperthyroidism	
Severe hypertension	
Heart failure	
Significant coronary artery disease	
Poorly controlled diabetes	
Severe chronic obstructive pulmonary disease	
Chronic renal disease	
Recent drug/alcohol abuse	
